Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Share-based Compensation for 10 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 82.51% to $19.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.8 million, a 68.38% increase, with the full-year FY2025 number at $66.8 million, up 68.38% from a year prior.
  • Share-based Compensation was $19.3 million for Q4 2025 at Rhythm Pharmaceuticals, up from $18.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $19.3 million in Q4 2025 to a low of $4.6 million in Q1 2022.
  • A 5-year average of $9.0 million and a median of $8.2 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: decreased 11.17% in 2022, then skyrocketed 82.51% in 2025.
  • Rhythm Pharmaceuticals' Share-based Compensation stood at $4.7 million in 2021, then increased by 13.07% to $5.3 million in 2022, then soared by 64.06% to $8.7 million in 2023, then increased by 21.7% to $10.6 million in 2024, then surged by 82.51% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Share-based Compensation are $19.3 million (Q4 2025), $18.8 million (Q3 2025), and $15.9 million (Q2 2025).